Parkman Healthcare Partners LLC Takes $12.97 Million Position in Danaher Corporation $DHR

Key Points

• Parkman Healthcare Partners LLC invested approximately $12.97 million in Danaher Corporation, purchasing 63,250 shares, which represents 1.5% of its portfolio.
• Analysts have mixed ratings on Danaher's stock, with a consensus price target of $246.35 and most brokerages maintaining Buy or Equal Weight ratings.
• Danaher reported a strong earnings performance in its latest quarter, with $1.80 earnings per share, exceeding analysts' expectations of $1.64.

Parkman Healthcare Partners LLC acquired a new stake in Danaher Corporation (NYSE:DHR - Free Report) during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 63,250 shares of the conglomerate's stock, valued at approximately $12,966,000. Danaher comprises about 1.5% of Parkman Healthcare Partners LLC's portfolio, making the stock its 26th biggest position.

Other hedge funds have also modified their holdings of the company. Bank Pictet & Cie Europe AG raised its holdings in Danaher by 22.8% in the fourth quarter. Bank Pictet & Cie Europe AG now owns 192,731 shares of the conglomerate's stock worth $44,241,000 after purchasing an additional 35,730 shares during the period. FORA Capital LLC acquired a new stake in Danaher in the fourth quarter worth $1,859,000. Ewing Morris & Co. Investment Partners Ltd. bought a new stake in shares of Danaher in the fourth quarter worth about $621,000. Ethic Inc. increased its holdings in shares of Danaher by 44.7% in the fourth quarter. Ethic Inc. now owns 56,333 shares of the conglomerate's stock worth $12,931,000 after acquiring an additional 17,402 shares in the last quarter. Finally, Ensign Peak Advisors Inc increased its holdings in shares of Danaher by 1.9% in the fourth quarter. Ensign Peak Advisors Inc now owns 1,306,654 shares of the conglomerate's stock worth $299,942,000 after acquiring an additional 24,888 shares in the last quarter. 79.05% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several equities research analysts have issued reports on DHR shares. Robert W. Baird increased their price target on Danaher from $225.00 to $226.00 and gave the stock an "outperform" rating in a report on Friday, July 18th. Royal Bank Of Canada set a $241.00 target price on shares of Danaher in a report on Tuesday, September 2nd. UBS Group dropped their target price on shares of Danaher from $240.00 to $225.00 and set a "buy" rating on the stock in a report on Wednesday, July 23rd. Barclays restated an "overweight" rating and set a $225.00 target price (up from $215.00) on shares of Danaher in a report on Tuesday, June 24th. Finally, Wells Fargo & Company dropped their target price on shares of Danaher from $210.00 to $205.00 and set an "equal weight" rating on the stock in a report on Wednesday, July 23rd. Seventeen analysts have rated the stock with a Buy rating and three have given a Hold rating to the company's stock. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $246.35.

Danaher Stock Down 2.2%

Shares of DHR traded down $4.39 during mid-day trading on Tuesday, hitting $194.24. 3,344,891 shares of the company's stock were exchanged, compared to its average volume of 2,899,976. The company has a market cap of $139.09 billion, a PE ratio of 41.33, a P/E/G ratio of 2.77 and a beta of 0.75. Danaher Corporation has a 52 week low of $171.00 and a 52 week high of $279.90. The company has a 50-day simple moving average of $201.82 and a 200 day simple moving average of $199.20. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.62 and a quick ratio of 1.22.

Danaher (NYSE:DHR - Get Free Report) last issued its quarterly earnings results on Tuesday, July 22nd. The conglomerate reported $1.80 earnings per share for the quarter, topping the consensus estimate of $1.64 by $0.16. The company had revenue of $5.94 billion during the quarter, compared to analysts' expectations of $5.83 billion. Danaher had a net margin of 14.21% and a return on equity of 10.70%. The business's quarterly revenue was up 3.4% on a year-over-year basis. During the same period last year, the business earned $1.72 EPS. Danaher has set its FY 2025 guidance at 7.700-7.800 EPS. On average, research analysts forecast that Danaher Corporation will post 7.63 earnings per share for the current fiscal year.

Danaher Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, October 31st. Stockholders of record on Friday, September 26th will be issued a $0.32 dividend. This represents a $1.28 annualized dividend and a dividend yield of 0.7%. Danaher's payout ratio is presently 27.23%.

Insider Activity at Danaher

In other news, Director Teri List sold 2,778 shares of the stock in a transaction that occurred on Friday, August 22nd. The stock was sold at an average price of $211.06, for a total value of $586,324.68. Following the completion of the sale, the director owned 20,751 shares of the company's stock, valued at approximately $4,379,706.06. This represents a 11.81% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Insiders own 11.20% of the company's stock.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.